EXEL News and Press, Exelixis Inc. From 01/18/24

Exelixis, Inc. (Nasdaq: EXEL) today announced it has successfully defended European Patent number EP2593090 (c-MET Modulator Pharmaceutical Compositions) against three opponents, STADA Arzneimittel AG, Teva Pharmaceutical Industries Ltd., and Generics (U.K.) Ltd. in a hearing before the Opposit...

2024-01-18 00:50:47 ET Summary Exelixis recently reported solid but not stellar 2023 financial results and provided guidance for 2024. The company expects a 2.5% increase in revenues from 2023 to 2024, with reductions in expenses. Key priorities for 2024 include corporate rest...

2024-01-17 04:22:07 ET Summary Exelixis Inc. is a biotech company focused on oncology, with its main products being Cometriq and Cabometyx, which are used for treating thyroid and kidney cancer. The company faces a legal battle against MSN Laboratories over Cabometyx's patents, wh...

2024-01-08 14:00:01 ET William Blair analyst issues OUTPERFORM recommendation for EXEL on January 8, 2024 02:12PM ET. The previous analyst recommendation was Outperform. EXEL was trading at $22.085 at issue of the analyst recommendation. The overall analyst consensus : B...

2024-01-08 11:37:56 ET More on Exelixis Exelixis: Earnings Sell-Off Presents Unique Opportunity Exelixis, Inc. 2023 Q3 - Results - Earnings Call Presentation Exelixis (EXEL) Q3 2023 Earnings Call Transcript Exelixis forecasts 2024 revenue between $1.83B - $1....

– Cabozantinib franchise achieves approximately $1.630 billion in preliminary U.S. net product revenues for fiscal year 2023 – – Fiscal year 2024 net product revenues guidance of $1,650 million - $1,750 million; 2024 R&D expense guidance of $925 million - $975...

2024-01-07 12:00:45 ET More on AbbVie, Bristol-Myers, etc. AbbVie: Still Expensive Despite The Great M&A Acumen Bristol-Myers Squibb Company (BMY) Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript) Merck & Co., Inc. (MRK) Goldman Sachs Health...

– Presentation to be webcast on www.exelixis.com – Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide a corporate overview at the 42 nd Annual J.P. Morgan ...

2023-12-21 13:05:16 ET Summary Valuations in the biotech market have fallen, making it a good time for acquisitions in the industry. Investors should focus on commercial-stage biotech companies that generate revenue, as they provide a safety net in uncertain economic conditions. ...

Exelixis, Inc. (Nasdaq: EXEL) today announced that it will webcast the Exelixis 2023 R&D Day: Science & Strategy event taking place on Tuesday, December 12, 2023, from 9:00 a.m. to 12:30 p.m. EST. During the event, featured speakers will review the progress of the company’s growing...